Omega Therapeutics, Inc. (OMGA)

Market Cap	321.93M
Revenue (ttm)	144,000
Net Income (ttm)	-92.73M
Shares Out	47.85M
EPS (ttm)	-2.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,108
Open	6.77
Previous Close	6.7
Day's Range	6.42 - 6.94
52-Week Range	1.98 - 18.61
Beta	n/a
Analysts	Buy
Price Target	15.91 (+137.1%)
Earnings Date	Nov 9, 2022

About OMGA

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, as well as the mechanism that controls gene expression and aspect of an organism's life. The company's platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a range without altering native nucleic acid sequences. Its modular and programmable mRNA medicines, and Omega Epigenomic Controllers are designed to tar...

• Industry: Biotechnology
• IPO Date: Jul 30, 2021
• Employees: 79
• Stock Exchange: NASDAQ
• Ticker Symbol: OMGA

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for OMGA stock is "Buy." The 12-month stock price forecast is 15.91, which is an increase of 137.11% from the latest price.

Price Target

$15.91

(137.11% upside)

Analyst Consensus: Buy

Stock Forecasts